DP Clinical Recognized by Canada’s Strategic Science Fund

ROCKVILLE, MD – October 26, 2022 – James (Jim) Hamer, Director, Spinal Cord Injury (SCI) Programs was recently recognized by the Canadian Government for his work with the Strategic Science Fund (SSF).  Jim served as a Technical Reviewer for the country’s new SSF program.  This program was implemented to improve the effectiveness of federal investments used to support third-party science and research organizations.  We congratulate Jim on being recognized as an expert in the field of SCI.  DP Clinical has proven experience conducting clinical programs in the SCI space. If you are looking for assistance with your next SCI clinical trial, contact DP Clinical at info@dpclinical.com.

DP Clinical Welcomes Timothy Urschel as Vice President, Regulatory Affairs/Quality Assurance

ROCKVILLE, MD – June 10, 2021 – DP Clinical, Inc., a Contract Research Organization (CRO) specializing in dermatology, infectious disease, neuroscience, oncology, and ophthalmology Phase I-III clinical programs; continues its growth with the addition of Tim Urschel as Vice President, Regulatory Affairs/Quality Assurance. Mr. Urschel joined the DP Clinical team in October 2020 and brings more than 25 years of experience in regulatory affairs and GxP quality assurance including regulatory GxP compliance and development of quality management systems in both GCP and GMP environments. His broad range of experience includes the development of regulatory strategies including NDAs, INDs, Annual Reports, Orphan Drug Applications, CTAs, and MAA applications.

Prior to joining DP Clinical, Mr. Urschel worked for Onconova Therapeutics, Inc. as a Vice President, Quality Assurance, where he was responsible for the overall quality assurance function to ensure compliance with federal and local regulations using a risk-based approach.

Mr. Urschel holds a BS degree in Medicinal Chemistry from the State University of New York at Buffalo and an MBA in Pharmaceutical Studies from Fairleigh-Dickinson University, Rutherford, New Jersey, and is a certified Quality Assurance Professional from the Society of Quality Assurance (SQA), an Accredited Clinical Researcher.

“Tim has touched every aspect of clinical research working at CROs, biotech, and pharmaceutical companies and is a proven leader in managing and building regulatory affairs and quality assurance functions in a competitive industry. We are excited to have him spearhead this initiative at DP Clinical,” stated Devinder Poonian, President and CEO.

DP Clinical Announces Database Lock of its First COVID-19 Clinical Trial ROCKVILLE, MD

ROCKVILLE, MD – February 19, 2021 – DP Clinical, Inc., a privately held Contract Research Organization (CRO), announced the database lock of its first COVID-19 clinical trial. Taking place the United States, the goal of the study was to determine a suitable dosage of a drug candidate for the treatment of severe acute respiratory syndrome-related Coronavirus 2 (SARS-CoV-2).

“We are proud to have been selected as the CRO partner to run this study,” said Devinder Poonian, President and CEO of DP Clinical. “DP Clinical is a CRO with significant infectious disease experience, and we worked closely with this Sponsor to meet timelines while remaining flexible — essential to staying ahead of the virus. This was DP Clinical’s first COVID-19 trial, and the company expects more COVID-19-related projects in the near future as sponsors continue to seek out CROs with experience in this indication.”

Jim Hamer Elected to Unite 2 Fight Paralysis (U2FP) Board of Directors

ROCKVILLE, MD – February 16, 2021 – DP Clinical, Inc., a Contract Research Organization (CRO) located in Rockville, Maryland, announces James (Jim) Hamer, Director, Spinal Cord Injury (SCI) Programs, at DP Clinical has been elected to the Board of Directors for Unite 2 Fight Paralysis (U2FP) organization and will serve a three-year term. U2FP’s mission is to unite and empower the international spinal cord injury community to cure paralysis through advocacy, education, and support for research.

“With more than 24 years of SCI research and clinical trial experience, Jim will bring a critical perspective to the Board,” stated Devinder Poonian, President and CEO of DP Clinical.  “During his career, Jim has managed numerous acute and chronic SCI clinical trials including those with pharmaceuticals, autologous macrophages, the first in human sub-acute stem cell trials, as well as device studies.  DP Clinical started as an SCI CRO, and we look forward to witnessing one-day soon a curative therapy for this debilitating injury,” continued Ms. Poonian.

DP Clinical Supports the Maryland Tech Council’s COVID-19 Campaign

As a Rockville, Maryland-based company, DP Clinical has joined forces with other companies throughout the state to show support and unity as we work together to combat the COVID-19 pandemic. We have joined with the Maryland Tech Council to spread the word – “We come together in adversity. We put our heads down to solve complex issues. We do whatever it takes. We are truly #bettertogether!”

At DP Clinical, we continue to work tirelessly to help everyone stay safe while at the same time continuing to serve our study Sponsors, Investigator sites, patients, and DP Clinical staff.
 

DP Clinical COVID-19 Update

At DP Clinical, we are monitoring the evolving news around COVID-19 and following the best practices provided by health organizations. We want you to know that the health and well-being of our team and yours is of the utmost importance to us and is guiding our decisions during this unprecedented time. DP Clinical has implemented its business continuity procedures, and our staff is working remotely with all systems and services in place to ensure business proceeds without interruption.  We are working tirelessly to help everyone stay safe while at the same time continuing to serve you. 

Please know we are always available to you by email or phone.

This is a difficult time for all those directly and indirectly affected by COVID-19, and we will strive to make sure we are doing everything possible to minimize risk for our staff, vendors, sites, and particularly patients.

Kind regards,

The DP Clinical Team

NEWS RELEASE: DP Clinical-Supported Study Results in FDA Approval of ADMA Biologics’ ASCENIV™

ROCKVILLE, MD – September 18, 2019 – DP Clinical, Inc., a Contract Research Organization (CRO) specializing in infectious disease, neuroscience, oncology, and ophthalmology Phase I-III clinical programs; congratulates ADMA Biologics’ on the approval of ASCENIV™ (immune globulin intravenous, human – slra 10% liquid). DP Clinical provided a full complement of CRO services for ADMA Biologics program (formerly referred to as RI-002) indicated for the treatment of Primary Humoral Immunodeficiency Disease (PIDD) in adults and adolescents. Click here to read more.

PRESS RELEASE: DP Clinical Puts Its Confidence in Comprehend for Strategic Shift

REDWOOD CITY, Calif., Aug. 12, 2019 /PRNewswire/ — DP Clinical, Inc. and Comprehend Systems, Inc. are joining forces to transition the Rockville, Maryland-based CRO from spreadsheets and EDC reports to a system that aligns study teams with visual data analytics, automated KRI monitoring with alerts, and fully-auditable task management workflow. Click here to read more.

PRESS RELEASE: DP Clinical, Inc. Celebrates 25 Years as a CRO Provider

ROCKVILLE, MD – July 15, 2019 – DP Clinical, Inc., a Contract Research Organization (CRO) specializing in infectious disease, neuroscience, oncology, and ophthalmology Phase I-III clinical programs; today announced that July 1st, 2019, marked the company’s 25-year anniversary providing CRO services to pharma, biotech, and medical device companies. Click here to read more.